Quantcast

Latest Blueprint Medicines Stories

2014-11-20 12:31:36

- Builds on Company's novel discovery of several kinase fusion genes in cancer - CAMBRIDGE, Mass., Nov.

2014-11-12 08:32:58

-Proceeds to support continued advancement of highly selective kinase inhibitors to genomically defined cancers, including first-in-class FGFR4 and KIT Exon 17 inhibitors- CAMBRIDGE, Mass.,

2014-09-19 08:23:55

--Genomic Data in Study Published in Nature Communications Suggests New Treatment Strategies for These Hard to Treat Women's Reproductive Cancers-- BALTIMORE and CAMBRIDGE, Mass., Sept.

2014-09-10 08:32:36

- Findings and research approach published in Nature Communications - CAMBRIDGE, Mass., Sept.

2014-09-08 12:28:40

- In vivo data support potential clinical benefit of first therapeutic to target a defined subset of liver cancer patients based on genetic profile - CAMBRIDGE, Mass., Sept.

2014-07-24 08:34:15

CAMBRIDGE, Mass., July 24, 2014 /PRNewswire/ -- Blueprint Medicines (Blueprint), a leader in discovering highly selective kinase inhibitors for genomically defined cancer patients, today announced


Word of the Day
ultimo
  • In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.
  • In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.
The word 'ultimo' comes from the Latin phrase 'ultimo mense', 'in the last month'.
Related